Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 8/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370285 | 0.91 | ROCK2 (0.39) | TACR3AKT1ROCK2CYP2C9TRPV1 | |
| SCHEMBL2370469 | 0.90 | AKT1 (0.45) | RIPK1TACR3SMYD3AKT1CDK2 | |
| SCHEMBL12301416 | 0.90 | CYP2C9 (0.47) | RIPK1TACR3AKT1ROCK2CYP2C9 | |
| SCHEMBL2371286 | 0.87 | CYP2C9 (0.44) | TACR3AKT1ROCK2CYP2C9TRPV1 | |
| SCHEMBL2370407 | 0.85 | TRPV1 (0.47) | TACR3ROCK2CYP2C9TRPV1 | |
| SCHEMBL2371290 | 0.85 | TACR3 (0.40) | TACR3CDK2ROCK2TRPV1 | |
| SCHEMBL1975767 | 0.81 | RIPK1 (0.42) | RIPK1TACR3SMYD3CYP2C9 | |
| SCHEMBL7946365 | 0.81 | TACR3 (0.45) | RIPK1TACR3SMYD3CYP2C9 | |
| SCHEMBL2370709 | 0.80 | CYP2C9 (0.45) | TACR3AKT1ROCK2CYP2C9TRPV1 | |
| SCHEMBL14562492 | 0.79 | KDM4C (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | claimed |
| WO-2011110183-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | WO | claimed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110183-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, KCND3 | RIPK1 2922/4885TACR3 12/4885SMYD3 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.